NASDAQ:CODX Co-Diagnostics (CODX) Stock Price, News & Analysis → CBOE shift unlocks new weekend income strategy (From DTI) (Ad) Free CODX Stock Alerts $1.14 +0.03 (+2.70%) (As of 09:02 AM ET) Add Compare Share Share Today's Range$1.14▼$1.1450-Day Range$1.06▼$1.3052-Week Range$0.98▼$1.89Volume1,785 shsAverage Volume64,562 shsMarket Capitalization$35.64 millionP/E RatioN/ADividend YieldN/APrice Target$2.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Co-Diagnostics alerts: Email Address Co-Diagnostics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside125.2% Upside$2.50 Price TargetShort InterestBearish1.22% of Shares Sold ShortDividend StrengthN/ASustainability-1.10Upright™ Environmental ScoreNews Sentiment0.30Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.37 out of 5 starsMedical Sector322nd out of 939 stocksSurgical & Medical Instruments Industry43rd out of 99 stocks 3.0 Analyst's Opinion Consensus RatingCo-Diagnostics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.50, Co-Diagnostics has a forecasted upside of 125.2% from its current price of $1.11.Amount of Analyst CoverageCo-Diagnostics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted1.22% of the outstanding shares of Co-Diagnostics have been sold short.Short Interest Ratio / Days to CoverCo-Diagnostics has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Co-Diagnostics has recently increased by 11.78%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCo-Diagnostics does not currently pay a dividend.Dividend GrowthCo-Diagnostics does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCo-Diagnostics has received a 67.43% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Diagnostic test kits", "Infectious disease diagnostics systems", and "PCR machines" products. See details.Environmental SustainabilityThe Environmental Impact score for Co-Diagnostics is -1.10. Previous Next 2.4 News and Social Media Coverage News SentimentCo-Diagnostics has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Co-Diagnostics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for CODX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows3 people have added Co-Diagnostics to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Co-Diagnostics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.40% of the stock of Co-Diagnostics is held by insiders.Percentage Held by InstitutionsOnly 14.99% of the stock of Co-Diagnostics is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Co-Diagnostics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Co-Diagnostics is -0.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCo-Diagnostics has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIWarning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…Watch the presentation here About Co-Diagnostics Stock (NASDAQ:CODX)Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Read More CODX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CODX Stock News HeadlinesMarch 21, 2024 | prnewswire.comCo-Diagnostics, Inc. CEO Delivers Manufacturing and Commercialization Update in Conference Keynote AddressMarch 19, 2024 | americanbankingnews.comHC Wainwright Lowers Co-Diagnostics (NASDAQ:CODX) Price Target to $2.50March 28, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 18, 2024 | prnewswire.comCo-Diagnostics, Inc. CEO to Deliver Keynote Address at MarketsandMarkets 2024 in London, EnglandMarch 17, 2024 | uk.finance.yahoo.comA Look At The Intrinsic Value Of Edel SE & Co. KGaA (ETR:EDL)March 17, 2024 | uk.news.yahoo.comHolby City star Rosie Marcel calls for Casualty not to kill off CharlieMarch 16, 2024 | finance.yahoo.comCo-Diagnostics Full Year 2023 Earnings: Misses ExpectationsMarch 16, 2024 | finance.yahoo.comWe Think Co-Diagnostics (NASDAQ:CODX) Needs To Drive Business Growth CarefullyMarch 28, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.March 15, 2024 | finance.yahoo.comCo-Diagnostics, Inc. (NASDAQ:CODX) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | finance.yahoo.comQ4 2023 Co-Diagnostics Inc Earnings CallMarch 15, 2024 | markets.businessinsider.comMaintaining Hold on Co-Diagnostics Amid Revenue Decline and Potential EUA BoostMarch 15, 2024 | finance.yahoo.comCODX Mar 2024 1.500 callMarch 14, 2024 | investorplace.comCODX Stock Earnings: Co-Diagnostics Misses EPS, Misses Revenue for Q4 2023March 14, 2024 | benzinga.comCo-Diagnostics: Q4 Earnings InsightsMarch 14, 2024 | prnewswire.comCo-Diagnostics, Inc. Reports Full Year 2023 Financial ResultsMarch 13, 2024 | benzinga.comEarnings Preview: Co-DiagnosticsMarch 13, 2024 | markets.businessinsider.comHere's what to expect from Co-Diagnostics's earningsMarch 7, 2024 | finance.yahoo.comCo-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Influenza Multiplex PCR TestFebruary 29, 2024 | morningstar.comCo-Diagnostics Inc Registered Shs CODXFebruary 29, 2024 | prnewswire.comCo-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2023 Earnings Release Date and WebcastFebruary 15, 2024 | seekingalpha.comCODX Co-Diagnostics, Inc.February 1, 2024 | finance.yahoo.comCo-Diagnostics, Inc. Shares List of Upcoming Industry Conferences and Events for February 2024January 3, 2024 | finance.yahoo.comCo-Diagnostics, Inc. to Host Booth at CES 2024 January 9-12December 29, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Natera (NTRA) and Co-Diagnostics (CODX)December 28, 2023 | benzinga.comCo-Diagnostics Stock (NASDAQ:CODX) Dividends: History, Yield and DatesDecember 27, 2023 | marketwatch.comCo-Diagnostics Shares Rise 21% After Submitting FDA Application For Covid-19 Test PlatformSee More Headlines Receive CODX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Co-Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/11/2021Today3/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:CODX CUSIPN/A CIK1692415 Webwww.codiagnostics.com Phone(801) 438-1036FaxN/AEmployees155Year FoundedN/APrice Target and Rating Average Stock Price Target$2.50 High Stock Price Target$2.50 Low Stock Price Target$2.50 Potential Upside/Downside+125.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,330,000.00 Net Margins-518.69% Pretax Margin-559.47% Return on Equity-35.37% Return on Assets-32.58% Debt Debt-to-Equity RatioN/A Current Ratio10.81 Quick Ratio10.52 Sales & Book Value Annual Sales$6.81 million Price / Sales5.10 Cash FlowN/A Price / Cash FlowN/A Book Value$2.81 per share Price / Book0.40Miscellaneous Outstanding Shares31,260,000Free Float30,510,000Market Cap$34.70 million OptionableOptionable Beta-0.67 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Dwight H. Egan (Age 71)Chairman & CEO Comp: $415.75kMr. Brian L. Brown CPA (Age 48)CFO & Company Secretary Comp: $338.92kMr. Richard David Abbott (Age 52)President Dr. Brent C. Satterfield Ph.D. (Age 47)Co-Founder & Member of Scientific Advisory Board Comp: $237.5kMr. Dan Bohrer CPAVice President of Finance & AccountingDr. Mark Poritz Ph.D.Chief Scientific OfficerMr. Andrew BensonHead of Investor RelationsDr. Mayuranki AlmaulaSenior Vice President of Overseas Operations & Strategic AlliancesMr. Cameron GundryHead of Commercialization LATAM/EURMs. Ivory ChangChief Regulatory Affairs OfficerMore ExecutivesKey CompetitorsRetractable TechnologiesNYSE:RVPSpectral AINASDAQ:MDAIFemasysNASDAQ:FEMYNeuroOne Medical TechnologiesNASDAQ:NMTCAkiliNASDAQ:AKLIView All CompetitorsInstitutional OwnershipCitadel Advisors LLCSold 11,300 shares on 2/15/2024Ownership: 0.000%Kestra Advisory Services LLCBought 10,047 shares on 2/14/2024Ownership: 0.453%Physician Wealth Advisors Inc.Sold 8,000 shares on 1/23/2024Ownership: 0.103%SMI Advisory Services LLCBought 17,499 shares on 1/12/2024Ownership: 0.057%View All Institutional Transactions CODX Stock Analysis - Frequently Asked Questions Should I buy or sell Co-Diagnostics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" CODX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CODX, but not buy additional shares or sell existing shares. View CODX analyst ratings or view top-rated stocks. What is Co-Diagnostics' stock price target for 2024? 1 Wall Street analysts have issued 1-year price targets for Co-Diagnostics' shares. Their CODX share price targets range from $2.50 to $2.50. On average, they expect the company's share price to reach $2.50 in the next year. This suggests a possible upside of 125.2% from the stock's current price. View analysts price targets for CODX or view top-rated stocks among Wall Street analysts. How have CODX shares performed in 2024? Co-Diagnostics' stock was trading at $1.33 at the start of the year. Since then, CODX stock has decreased by 16.5% and is now trading at $1.11. View the best growth stocks for 2024 here. Are investors shorting Co-Diagnostics? Co-Diagnostics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 381,500 shares, an increase of 11.8% from the February 29th total of 341,300 shares. Based on an average daily volume of 90,100 shares, the days-to-cover ratio is presently 4.2 days. View Co-Diagnostics' Short Interest. When is Co-Diagnostics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CODX earnings forecast. How were Co-Diagnostics' earnings last quarter? Co-Diagnostics, Inc. (NASDAQ:CODX) released its quarterly earnings data on Thursday, November, 11th. The company reported $0.38 EPS for the quarter, topping the consensus estimate of $0.21 by $0.17. The firm had revenue of $30.10 million for the quarter, compared to the consensus estimate of $24 million. Co-Diagnostics had a negative net margin of 518.69% and a negative trailing twelve-month return on equity of 35.37%. During the same period in the previous year, the business earned $0.53 earnings per share. What other stocks do shareholders of Co-Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Moderna (MRNA), Vaxart (VXRT), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), iBio (IBIO), Advanced Micro Devices (AMD), Pfizer (PFE) and Johnson & Johnson (JNJ). When did Co-Diagnostics IPO? Co-Diagnostics (CODX) raised $9 million in an initial public offering (IPO) on Thursday, July 13th 2017. The company issued 1,300,000 shares at a price of $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities served as the underwriters for the IPO. Who are Co-Diagnostics' major shareholders? Co-Diagnostics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Kestra Advisory Services LLC (0.45%), Physician Wealth Advisors Inc. (0.10%), SMI Advisory Services LLC (0.06%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Brian Lee Brown, Eugene Durenard and Reed L Benson. View institutional ownership trends. How do I buy shares of Co-Diagnostics? Shares of CODX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CODX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Co-Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.